We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Kintara Therapeutics Inc (KTRA) USD0.001

Sell:$0.18 Buy:$0.20 Change: $0.004 (2.13%)
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Change: $0.004 (2.13%)
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
Change: $0.004 (2.13%)
Market closed |  Prices as at close on 27 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.

Contact details

9920 Pacific Heights Blvd
Suite 150, Suite 200
United States
+1 (858) 3504364

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$10.68 million
Shares in issue:
65.53 million
United States
US dollar

Key personnel

  • Robert Hoffman
    Chairman of the Board, President, Chief Executive Officer
  • Scott Praill
    Chief Financial Officer
  • John Liatos
    Senior Vice President, Business Development
  • Dennis Brown
    Chief Scientific Officer
  • Steven Rychnovsky
    Vice President - Research & Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.